Acomplia Diet Pill Pulled Back from FDA
The advisory channel to the FDA voted that the agency should not approve it due to the psychiatric risks observed from the use of Acomplia/Zimulti, the diet pill scientifically known as rimonabant from Sanofi-aventis.
Its company has withdrawn its application for U.S. approval because they lacked the time to fix the problems.
Marc Cluzel, a senior vice president of scientific and medical affairs at Sanofi, said on the conference call that the company is committed to getting the medicine approved in the U.S. Sanofi will meet with the regulator soon to try to better understand what’s needed to prove the drug’s safety, he said.
Aside from usual side digestive system effects from weight loss pills such as gas and diarrhea, users of Alli should also take note of another side effect – vitamin deficiency.



Comment